As in all RNA viruses, influenza viruses change and mutate constantly because their RNA polymerase has no proofreading ability. This poses a serious threat to public health nowadays. Also, traditional pathogen-based detection methods may not be able to report an infection from an unknown type or a subtype of virus if their nucleotide sequence is not known. Because of these, targeting host microRNA signatures may be an alternative to classify infections and distinguish types of pathogens as microRNAs are produced in human shortly after infection. Although this approach is in its infant stage, there is an urgent need to develop a rapid reporter assay for microRNA for disease control and prevention. As a proof of concept, we report here for the first time a non-PCR MARS (MicroRNARNase-SPR) assay to detect the microRNA miR-29a-3p from human subjects infected with influenza virus H1N1 by surface plasmon resonance (SPR). In our MARS assay, RNase H is employed to specifically hydrolyze the RNA probes immobilized on the gold surface where they hybridize with their cognate target, the cDNAs of miR-29a-3p from reverse transcription with stem-looped primers. After the digestion of the RNA probe by RNase H, the intact cDNA was released from the RNA-DNA hybrid and bound to a new RNA probe for another enzymatic reaction cycle to amplify signals. With assay optimization, the detection limit of our MARS assay for miR-29a-3p was found to be 1 nM and this new assay could be completed within 1 hour without thermal cycling. This non-PCR assay with high selectivity for mature microRNA provides a new platform for rapid disease diagnosis, quarantine and disease control.
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Analyst www.rsc.org/analyst high homology in sequence among family members. For miRs sensing, real-time quantitative polymerase chain reaction (RT-qPCR), Northern blot analysis and microarray-based scanning are widely used among other detection techniques. However, each platform has its own advantages and disadvantages [9] .
In this study, we introduced a new method called MARS (MicroRNA-RNase-SPR) assay using ribonuclease H (RNase H) and surface plasmon resonance (SPR) to sense a marker miR, miR-29a-3p, associated with influenza viral infection. RNase H is a sequence non-specific endonuclease found in the HIV-1 (human immunodeficiency virus type-1) and some other prokaryotes and eukaryotes.
During HIV-1 infection, the RNA from the virus is reversibly transcribed into cDNA and the retroviral RNase H degrades the RNA in the RNA-DNA hybrid leaving the cDNA in host cells for viral replication [10, 11] .
It has been known for a while that mature miRs with 5'-end variations are generated from the primary miR transcripts by Drosha alternative processing [12] . To perform the MARS assay, a particular form of mature miR among other variants are first reversely transcribed into cDNA using stem-loop primers ( Figure 1) . Notably, the stem-loop at 5'-end is able to block the primers from annealing to other mature variants and the miR precursors (e.g. primary and pre-miRs), thus increasing the specificity and efficiency in the conversion of a distinct form of mature miR to cDNA [13] .
On the SPR surface, miR probes with spacer at 3'-end and biotin at 5'-end are immobilized on the precleaned gold surface by 3'-thiolated linkage via self-assembly. Unlike proteins, our miR probes and cDNAs are small (i.e. short length oligonucleotide) in nature, therefore association or dissociation does not change the SPR signals much. To increase SPR signals, streptavidins are added to the RNA probes through biotin-avidin interaction [14] . After washing, the surface is used to capture target cDNAs. RNase H is then introduced to the SPR chamber to digest the cDNA-bound RNA probes conjugated with streptavidin. Subsequently, the released cDNA binds to another miR probe for digestion. Cycle of reaction continues and most, if not all, the probes are cleaved and a change in SPR signals is generated (Figure 1 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   Analyst Accepted Manuscript 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analyst Accepted Manuscript
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Experimental Section
Materials and Reagents
Key reagents were obtained from the following sources. Chemicals for SPR sensing were purchased from Aladdin Reagent (Shanghai, China). Recombinant E. coli prokaryotic RNase H (molecular size:
18.5 kDa, original concentration of 60,000 U/mL) and RNase III (molecular size: 25.6 kDa, original concentration of 1,000 U/mL) were purchased from Takara Biotechnology (Dalian, China) and Life Technologies, respectively. Streptavidin was obtained from Bioss (China). All glasswares, pipette tips and solutions were autoclaved and cleaned with RNase AWAY Decontamination Reagent (Life Technologies) before use. The DNA and RNA sequences used in this study are summarized in Table 1 . Table 1 . The DNA and RNA sequences used in this study (Capital = DNA, small letter = RNA)
Name
Sequence ( The mature miR probes for the cDNA of hsa-miR-29a-3p (5'-taaccgatttcagatggtgcta-3') and miR-181-5p (5'-actcaccgacagcgttgaatgtt-3') were purchased from Takara Biotechnology (Dalian, China), with biotin at the 5'-end for streptavidin attachment for signal enhancement, and C-6 spacer at the 3'-end with thiol group for self-assembly onto the SPR gold surface. To prepare the sensing surface, 1 µM RNA probe in 0.2 µL sodium acetate buffer (5 mM sodium acetate at pH 7.8) was added on the SPR 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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SPR detection
Synthetic ssDNA mimicking the reversely transcribed cDNA from the hsa-miR-29a-3p was obtained from Takara Biotechnology (Dalian, China). One hundred µM stock solution was made using ddH 2 O. ssDNA of various concentrations were then prepared in the SPR binding buffer and subjected to SPR detection at 25 o C. The ssDNA was injected into the SPR sensing chamber with a flow rate at 50 µL/min for 10 min. The chamber was then rinsed with buffer to obtain a steady baseline. RNase H (60 U/mL) was subsequently injected at a flow rate of 50 µL/min for 15 min, the gold surface was rinsed with buffer again to obtain a steady baseline. The intensity difference before and after RNase H addition was recorded. value, was performed to confirm the relative fold change difference of the miR-29a-3p cDNA between healthy donors and H1N1 patients. Ct value is the PCR cycle number that gives a detectable amplification signal (threshold) from reactions. The lower the Ct value, the more is the initial cDNA copies for PCR amplification.
Patient miR detection
Statistical analysis
Results are mean±SD from at least three independent assays unless otherwise stated. All of the experimental results were analyzed by Student's t-test, p-values less than 0.05 were considered statistically significant. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60
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Results miR quantitation and signal enhancement by biotin-streptavidin in the MARS assay SPR detection is sensitive to small changes in the refractive index of materials at the interface between a thin gold film and a bulk solution [16, 17] . Although it is a label-free techique that quantifies biomolecular interactions, binding of streptavidin to the biotinlated RNA probes immobilized on gold surface was employed in our study to amplify the SPR signals and enhance the SPR sensing sensitivity.
As shown in a typical set of sensorgrams in Figure 2 , hybridization between the DNAs of known concntrations and its corresponding RNA probe with streptavidin showed a stronger increase in the SPR signals ( Figure 2A ) than that without streptavidin ( Figure 2B ). Obviously, our data show that streptavidin did not interfere with the binding of DNA to the RNA probes ( Figure 2A ). For the signals generated by enzyme digestion, a deeper decrease in the SPR signals (signal change ~10-fold) was obtained from the probes with streptavidin 100 sec after the addition of RNase H ( Figure 2C ) when comapred to that without streptavidin ( Figure 2D ). Experiments were repeated thrice and data extracted from these experiemnts. As can be seen in Figure 2E , the SPR readouts started to show a significant change from the DNA samples 20 nM onwards. These results indicate that using biotinstreptavidin in our platform could significantly improve the signal-to-nosie ratio and assay sensitivity.
Next, we tried to establish the limit of detection (LOD) for our MARS plateform. According to the definition of LOD (the lowest concentration of a substance that can be distinguished from blank without that substance), LOD was calculated as signal at blank plus three times of standard deviation followed the recommendation by the IUPAC (International Union of Pure and Applied Chemistry), i.e. 0.0036 + (3 x 0.0003) = 0.0045 intensity level, corresponding to a concentration below 1 nM (Fig.2F) .
For quantitative detection, we used limit of quantitation (LOQ, the limit at which one can differentiate the difference between two different values), which was defined as signal at blank plus ten times of standard deviation, i.e. 0.0036 + (10 x 0.0003) = 0.0066. As RNase H generates a negative SPR signal after digesting the probes, the LOQ (-0.0066) will fall within the range 0 nM (0.0036) to 1 nM (-0.0491) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analyst Accepted Manuscript (Fig.2F ). It appears that the detection limit of our MARS platform could reach <1 nM for quantitation.
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For the relationship between SPR signal and miR concentration, there is a negative relationship between the data, i.e. a negative slope of -0.0026 from 10-100 nM of miR without using biotinstreptavidin, while -0.0076 from 1-70 nM and -0.073 from 70-100 nM with the biotin-streptavidin enhancement (Fig. 2E) . The larger magnitude of the negative slope indicates that the SPR signal changes more dramatically when the miR concentration is larger than 70 nM in the presence of biotin-streptavidin.
Specificity in the MARS assay
Specificity is another important concern for our MARS sensors. Specificity is evaluated by real-time SPR imaging based on hybridization between immobilized probes and testing ligands, and subsequent digestion of the RNA probes on the gold SPR surface by the RNase H. As can be seen in Figure 3 , single stranded DNA (ssDNA) probe for miR-29a-3p and miR probes for hsa-miR-29a-3p and hsa-miR-181-5p
were immobilized on different sensing areas of one sensor chip. Subsequently, cDNAs of hsa-miR29a-3p and hsa-miR-181-5p, RNase H and buffer were added at the time points (i-v) as indicated.
Panel A in Figure 3 shows a sensorgram for the ssRNA probe miR-29a-3p. As can be seen, a small increase in signal after the injection of cDNA of miR-29a-3p at time point 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In Panels F and G (Figure 3) , we repeated the assay using RNase III instead of RNase H with the cDNA of miR-29a-3p (Panel F) or ssRNA of miR-29a-3p (Panel G) on the sensing chip of the same configuration as mentioned in Panels A-E. RNase III is an enzyme that digests dsRNA to dsRNA fragments of ~12 bp long but not other formats such as the dsDNA or RNA-DNA hybrids [18] . For clear comparison, we set the sensorgrams from the 4 regions of chip to the same baseline no matter if a hybridization had occurred or not. RNase III was then introduced into the system. Maybe due to a large amount of the RNase III used, (although only 5 U/mL had been used in the assay (vs. 60 U/mL of RNase H)), an immediate increase in the SPR intensity was observed in both panels indicating the association of the enzyme on the sensing surface. As can be seen in Panel F with the in-flow cDNA, no signal decrease was observed and all four time-course tracings were more or less the same. These indicate that the RNase III did not cleave any probes on the SPR surface since no dsRNA was present on the sensing surface.
On the contrary, a significant decrease in SPR signal was obtained only from the region with the cognate RNA probe in Panel G with the in-flow ssRNA. No such change was found from the region specificity between the precise hybridization of probes to their corresponding targets and the specific enzyme activity from RNase H but not others such as the RNase III contamination in the MARS assay.
Using the MARS assay to detect the miR-29a-3p from the patients infected with H1N1
To demonstrate the utility of our new detection platform, we utilized a pilot samples from 20 patients with H1N1 influenza virus infection collected during the seasonal influenza period in April 2014.
Disease status of subjects was first confirmed by the RT-qPCR with specific primers against the H1N1 marker RNA as described in 'Experimental Section'. As shown in Figure 4A , signals from the healthy subjects remained at background level until the end of the experiment. On the contrary, remarkable increase in fluorescent signals was obtained from patient sample after 25 cycles suggesting that the samples were H1N1 positive.
Next, RNAs were extracted from the throat swabs of subjects with influenza virus H1N1 infection, and that of healthy donors for comparison. For the detection of miR, mature hsa-miR-29a-3p was first reversely transcribed into cDNA with stem-loop primers. As mentioned before, this method can pick up the mature miR selectively and effectively, and eliminate the pre-mature miR or other isoforms generated by alternative Drosha processing [12] . Total RNA (10 ng) from each individual was subject to reverse transcription and analysized via both MARS assay and real-time qPCR.
As can be seen from the MARS assay ( Figure 4B ), patient samples showed a bigger change for miR29a-3p. With the information from standard curves, the miR-29a-3p level from patients and healthy subjects were found to be 6.8 ± 2.4 and 17.8 ± 2.4 nM respectively. The same preparations were then re-examined using RT-qPCR assay. Again, the miR-29a-3p was found to be downgulated by a Ct difference of 1.92 from the disease samples ( Figure 4C ). For these results, it is noteworthy that only 30 minutes (i.e. 15 min for cDNA-RNA hybridization and 15 min for RNase H action) were required to complete the MARS assay while more than 3 hours were needed for the RT-qPCR. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
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Influenza viruses are the enveloped RNA virus belonging to the Orthomyxoviridae family. They remain one of the major public health threats of this centry [19] . With the antigenic drift by RNA polymerase errors and antigenic shift by gene reassortment, new strains of pathogen may appear which are not recognized by human defence system after vaccination and may thus cause epidemics and pandemics [8] .
Although still in its infant stage, global miR profiling will potentially identify miR signatures as the biomarkers of influenza [20] . In this study, we reported a new and rapid diagnostic method using RNase H to detect host miR. Using conventional RT-qPCR and our MARS assay, we found miR-29a-3p was down-regulated in the throat swabs of the subjects infected with influenza A virus H1N1 ( Figure   4 ). In the miR-29 family, there are three members, namely, miR-29a, miR-29b, and miR-29c. In particular, miR-29 was found to suppress the host immune response by targeting interferon-gamma in mouse model [21] . Moreover, expression of miR-29c, associated with NF-κB activity, significantly inhibited the production of several anti-viral and pro-inflammatory cytokines in the H1N1-infected in vitro model [22] . As the alignment score between the miR-29a and miR-29c is high, it is likely that the down-regulated level of miR-29a found in the throat swabs from the subjects with H1N1 infection may indicate a protective response generated from host against the H1N1.
In our MARS system, we used RNase H to digest the RNA probes on the gold SPR surface and the LOD was found to be 1 nM. Practically, the stability of our RNA probe was found surprisingly high. Storage of the probes at 4 o C up to two weeks did not affect the efficiency on cDNA binding and SPR signals (Supplementary Figure 1) . This may be due to the fact that the sequence of our probe is indeed a miR, which is highly stable. Results from literature indicate that miR remained intact even in the formalin- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analyst Accepted Manuscript starts from the fourth nucleotide from the 5'-end [24, 25] . It can be imagined that the longer the RNA-DNA hybrid length, the more the RNA site can be cleaved by the RNase H. To meet this requirement, our miR-29a-3p probe was 100% RNA and contained a total of 22 bases which provides multiple sites for hydrolysis. Also, this design reduces the possible steric hindrance problem from streptavidin thereby improving the assay sensitivity and detection limit.
Experimentally, we found that 200 µL out of 5 mL of throat swab saline yielded more than 100 ng RNA which was sufficient for SPR sensing. Taking the volume of cDNA injected (500 µL) into the account, the detection limit of our MARS assay was 500 fmol in our experimental condition (60 U/mL RNase H 15 min action, 25 o C). It matched with other SPR detection methods with a detection limit at femtomole level [26, 27] . Although the detection limit of some other methods such as RT-qPCR reaches fM level, they took a much longer time for sensing [13] .
Unlike RT-qPCR using beta-actin or GAPDH for normalization, we could not identify a suitable housekeeping miR for data normalization. In fact, there are findings showing that different tissue has different endogenous miR references [28] . To solve this problem, we normalized our samples by the RNA input amount. In this connection, more work is needed to identify a suitable miR reference for normalization for throat swab samples.
In our study, a 2 x 2 array and SPR imaging were employed to test the assay specificity ( Figure 3 ). It is anticipated that a more high throughput MARS microarray (n x n) can be used to detect the miR signatures for influenza if more information from research (e.g. miR control for normalization) and the global miR profiling are available. Once the database is provisioned, the pattern of infectioninduced miR change can be used as a barcode for disease identification.
Conclusions
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